11 results about "Nucleotidase" patented technology

The invention provides a uracil production strain and a construction method and application thereof.According to the strain, on an E.coli UR14 genome by means of a CRIPSR / Cas9 gene editing technology, firstly, psuG genes, preTA genes, rutA genes and upp genes are knocked out, so that decomposition of uracil is blocked; then, a uridine phosphorylase gene udp and a pyrimidine-5 '-nucleotide nucleotidase gene ppnN are subjected to overexpression, and synthesis and accumulation of uracil are synergistically enhanced; and finally, overexpression of the ribose phosphate mutase gene pgm further enhances the conversion of a by-product ribose phosphate 1-precursor 5-ribose phosphate 1-pyrophosphate and improves the carbon utilization rate, and the obtained strain has good genetic stability and high fermentation yield, can stably produce uracil, and has wide application prospects.

The present invention relates to radio- and fluorescence-labeled compounds, as well as their use as Diagnostics for Detecting Ecto-5′-Nucleotidase (CD73). The invention is further directed to a pharmaceutical composition comprising said compounds as well as to the compounds and the pharmaceutical composition for use in a method of diagnosis of a disease associated with increased or decreased CD73-expression as well as in the treatment of a disease associated with increased CD73-expression.

Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and / or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

Provided are CD73 (also known as ecto-5'-nucleotidase) inhibitor compounds, and compositions and uses thereof for treating and / or preventing CD73-associated diseases, disorders, and conditions, including cancer-associated and immune-associated disorders. CD73 inhibitor compounds include compounds having a structure according to Formula I': (I') and pharmaceutically acceptable esters or salts thereof.

The invention provides application of non-specific 5 '-nucleotidase in production of beta-nicotinamide ribose (NR), and belongs to the technical field of biology. The invention discovers that the non-specific 5 '-nucleotidase derived from specific bacteria has obviously better catalytic activity for catalyzing the hydrolysis of nicotinamide nucleotide (NMN) to generate beta-nicotinamide ribose (NR) compared with UshA derived from escherichia coli, and the 5'-nucleotidase can be used for large-scale industrial production of beta-nicotinamide ribose.

CD73 (also known as ecto-5′-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I′ and pharmaceutically acceptable esters or salts thereof.

The invention relates to the technical field of in-vitro detection reagents, in particular to a 5 '-nucleotidase calibrator and a preparation method thereof.The calibrator comprises 5'-nucleotidase, a borate buffering agent and animal serum, and the animal serum is selected from at least one of newborn calf serum, fetal calf serum, calf serum or sheep serum. The calibrator disclosed by the invention shows good stability and interchangeability, and ensures the detection accuracy of 5 '-nucleotidase.

This invention involves immunizing mice with human ecto-5′-nucleotidase (CD73) to obtain multiple monoclonal antibodies whose heavy-chain and light-chain sequences are both novel amino acid sequences and which can be used to prepare CD73 enzyme activity inhibitors and anti-tumor drugs.

The purpose of the present invention is to provide a novel method which makes it possible to produce a methyl compound by using a general organic raw material such as glycine, serine, formic acid, methanol, or glucose to efficiently regenerate SAM and promote a methylation reaction.　The present invention provides a method for producing a methyl compound using a cell in which the activity or expression of S-adenosylmethionine (SAM)-dependent methyltransferase and S-ribosylhomocysteine lyase (LuxS) is increased and which has been modified so as to reduce enzymatic activity of at least one selected from the group consisting of 5'-nucleotidase (UshA, UmpG, and / or UmpH), AMP nucleosidase (Amn and / or PpnN), adenine deaminase (AdeD), adenylate cyclase (CyaA), and S-adenosylmethionine decarboxylase (SpeD).

The present invention provides for compositions and methods for deploying ddhNTPs as immunomodulatory therapeutics to modulate P2 receptors, as nucleotidase inhibitors, for applications like host-acting anti-infectives, oncolytics, anti-aging agents, or tissue regeneration agents.